



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Han-Mo KOO *et al.*

Appl. No.: 09/942,940

Confirmation No. 8963

Filed: August 31, 2001

For: INHIBITION OF MITOGEN-ACTIVATED
PROTEIN KINASE (MAPK) PATHWAY: A
SELECTIVE THERAPEUTIC STRATEGY
AGAINST MELANOMA

Art Unit: 1642

Examiner: Minh Tam Davis

Atty. Dkt. No. 38345-174995

Customer No.



26694

PATENT TRADEMARK OFFICE

TECH CENTER 1600/2900

MAR 25 2003

RECEIVED

W/ EXT (2) #6
1642
3/26/03

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper responds to the Office Action (Restriction Requirement) mailed 18 December 2002, the response to which is extended two months to 18 March 2003, with the accompanying Petition for Extension of Time and a check paying the extension fee.

According to the Office, the application contains claims directed to 10 distinct inventions that are linked by "linking" or generic claims 1 and 8.

Claim 1 and its dependent claims are directed to a method of killing melanoma cells. This claim is considered to be the linking claim for Groups I-V.

Claim 8 is directed to a method of protecting against melanoma in a susceptible subject. There were no dependent claims derived from claim 8. Claim 8 was considered to be a linking claim for inventions V-X.

Claim 9 and its dependent claims are directed to a method of inducing an antitumor response in a mammal having melanoma. Claim 9 was not designated to be a linking claim; claims 10-15 depend therefrom. Claim 9 and various of its dependent claims are included in each of Groups I-IV.